Florfenicol,Mometasone Furoate,Terbinafine Hydrochloride

Verify with FDA CVM →

21 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
6
Deaths Reported
2860.0%
Death Rate

Active Ingredients

Florfenicol,Mometasone Furoate,Terbinafine Hydrochloride

Administration Routes

Auricular (Otic)UnknownTopical

Species Affected

Dog 19
Cat 2

Most Affected Breeds

Crossbred Canine/dog 3
Retriever - Golden 2
Shih Tzu 2
Pug 2
Poodle - Toy 1
Chihuahua 1
Domestic Longhair 1
Domestic Shorthair 1
Siberian Husky 1
Terrier - Yorkshire 1

Most Reported Reactions

Falling 6
Lethargy (see also Central nervous system depression in Neurological) 5
Vestibular disorder NOS 5
Ocular discharge 4
Eye disorder NOS (for Photophobia see neurological) 4
Death by euthanasia 4
Nystagmus 4
Corneal ulcer 4
Cloudy eye (for Miosis, Mydriasis, Anisocoria, Nystagmus - see Neurological) 4
Circling - neurological disorder (see also Behavioural disorders) 4
Other abnormal test result NOS 4
Not sleeping 3

Outcome Breakdown

Outcome Unknown
8 (38.1%)
Ongoing
6 (28.6%)
Euthanized
4 (19.0%)
Died
2 (9.5%)
Recovered/Normal
1 (4.8%)

Data Summary

Metric Value
Total adverse event reports 21
Reports involving death 6
Case-fatality rate (reported events) 2860.0%
Distinct species in reports 2
Distinct breeds in reports 16
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Florfenicol,Mometasone Furoate,Terbinafine Hydrochloride Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 21 adverse event reports referencing Florfenicol,Mometasone Furoate,Terbinafine Hydrochloride, including 6 reports in which the animal died — a 2860.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Florfenicol,Mometasone Furoate,Terbinafine Hydrochloride. Reported administration routes include Auricular (Otic), Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Florfenicol,Mometasone Furoate,Terbinafine Hydrochloride reports are Dog (19 reports), Cat (2 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (3), Retriever - Golden (2), Shih Tzu (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Florfenicol,Mometasone Furoate,Terbinafine Hydrochloride are Falling (6), Lethargy (see also Central nervous system depression in Neurological) (5), Vestibular disorder NOS (5), Ocular discharge (4). Of the 21 reports with a coded outcome, Outcome Unknown is the leading category at 38.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Florfenicol,Mometasone Furoate,Terbinafine Hydrochloride.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial